NEW YORK, NY / ACCESSWIRE / July 27, 2020 / Alpha Bronze, LLC ("Alpha Bronze"), is pleased to announce that Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company ...

Figure 3: Reaction of the Wza mutant Y110G/K375C with MTSES. Figure 6: Interaction of am 8 γCD 13 with the α-helix barrel of Wza mutants and proteolysed WT Wza.

AURORA, Ontario, June 23 Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) today announced positive Phase II pharmacokinetic ("PK") findings for Topical Interferon Alpha-2b in patients with ...

"This is a significant step for Helix. We are seeking approval to conduct what we intend to be a second, confirmatory efficacy trial of Topical Interferon Alpha-2b in patients with low-grade cervical ...